Evidence map›Paper›PMID 27716106›Full record

ArticleBMC microbiology2016

In vivo functional and molecular characterization of the Penicillin-Binding Protein 4 (DacB) of Pseudomonas aeruginosa.

Cristian Gustavo Aguilera Rossi, Paulino Gómez-Puertas, Juan Alfonso Ayala Serrano

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Class C β-Lactamases: Molecular Characteristics.Clinical microbiology reviews · 2022
    Review
  11. Article
  12. Peptidoglycan enzymes ofFrontiers in microbiology · 2022
    Review
  13. β-lactam Resistance inPathogens (Basel, Switzerland) · 2021
    Review
  14. Article
  15. Constructing and deconstructing the bacterial cell wall.Protein science : a publication of the Protein Society · 2020
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Cristian Gustavo Aguilera RossiDepartamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile.
Paulino Gómez-PuertasGrupo de Modelado Molecular, Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid-CSIC, Madrid, Spain.
Juan Alfonso Ayala SerranoLaboratorio de División Celular Bacteriana y Resistencia a Antibióticos, Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid-CSIC, Madrid, Spain. jayala@cbm.csic.es.
Universidad Autónoma de Madrid · ESUniversidad de La Frontera · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommunity and nosocomial infections by Pseudomonas aeruginosa still create a major therapeutic challenge. The resistance of this opportunist pathogen to β-lactam antibiotics is determined mainly by production of the inactivating enzyme AmpC, a class C cephalosporinase with a regulation system more complex than those found in members of the Enterobacteriaceae family. This regulatory system also participates directly in peptidoglycan turnover and recycling. One of the regulatory mechanisms for AmpC expression, recently identified in clinical isolates, is the inactivation of LMM-PBP4 (Low-Molecular-Mass Penicillin-Binding Protein 4), a protein whose catalytic activity on natural substrates has remained uncharacterized until now.

resultsWe carried out in vivo activity trials for LMM-PBP4 of Pseudomonas aeruginosa on macromolecular peptidoglycan of Escherichia coli and Pseudomonas aeruginosa. The results showed a decrease in the relative quantity of dimeric, trimeric and anhydrous units, and a smaller reduction in monomer disaccharide pentapeptide (M5) levels, validating the occurrence of D,D-carboxypeptidase and D,D-endopeptidase activities. Under conditions of induction for this protein and cefoxitin treatment, the reduction in M5 is not fully efficient, implying that LMM-PBP4 of Pseudomonas aeruginosa presents better behaviour as a D,D-endopeptidase. Kinetic evaluation of the direct D,D-peptidase activity of this protein on natural muropeptides M5 and D45 confirmed this bifunctionality and the greater affinity of LMM-PBP4 for its dimeric substrate. A three-dimensional model for the monomeric unit of LMM-PBP4 provided structural information which supports its catalytic performance.

conclusionsLMM-PBP4 of Pseudomonas aeruginosa is a bifunctional enzyme presenting both D,D-carboxypeptidase and D,D-endopeptidase activities; the D,D-endopeptidase function is predominant. Our study provides unprecedented functional and structural information which supports the proposal of this protein as a potential hydrolase-autolysin associated with peptidoglycan maturation and recycling. The fact that mutant PBP4 induces AmpC, may indicate that a putative muropeptide-subunit product of the DD-EPase activity of PBP4 could be a negative regulator of the pathway. This data contributes to understanding of the regulatory aspects of resistance to β-lactam antibiotics in this bacterial model.

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-Lactam Resistancebeta-LactamsCarboxypeptidasesCefoxitinCross InfectionDNA, BacterialEndopeptidasesEnzyme ActivationEscherichia coliEscherichia coli ProteinsModels, MolecularPenicillin-Binding ProteinsPeptidoglycanPseudomonas aeruginosaAnti-Bacterial AgentsBacterial Proteinsbeta-LactamsCarboxypeptidasesCefoxitinDNA, BacterialEndopeptidasesEscherichia coli ProteinsPenicillin-Binding ProteinsPeptidoglycanRecombinant ProteinsCatalytic functionD,D-peptidaseLMM-PBP4Macromolecular peptidoglycanPseudomonas aeruginosaPurified muropeptidesThree-dimensional structure

Identifiers

PMID27716106
PMCPMC5054556
OpenAlexW2529748653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.